BioWorld

Nov. 15, 2005

Viventia Merging, Becoming Private: C$12M To Pay Debt

PDUFA Being Reviewed Prior To Reauthorization

Speedel Presents Confirmatory Positive SPP301 Phase II Data

Other News To Note

OSI, Eyetech Close Merger After Look At Lucentis Data

Although it had to work on the weekend to calm any fears, OSI Pharmaceuticals Inc. closed its merger with Eyetech Pharmaceuticals Inc. Monday - much to the chagrin of some OSI analysts and investors. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...